Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prostate Cancer Patients Receiving Seed Implants Have High Survival Rates

By HospiMedica staff writers
Posted on 13 Feb 2007
More than 90% of men who receive appropriate radiation dose levels with permanent radiation seed implants to treat their prostate cancer are cured of their cancer eight years after diagnosis, according to investigators.

Seed implants have become a widely-accepted treatment alternative for early stage prostate cancer because it is very effective at curing the cancer, is minimally invasive and frequently spares patients from side effects of other treatments, such as impotence and incontinence. More...
The seeds, similar in size to a grain of rice, contain a radiation dose that, once implanted, delivers concentrated radiation to the prostate, sparing surrounding organs and tissue.

In this study, published in the February 1, 2007, issue of the International Journal for Radiation Oncology*Biology*Physics, researchers evaluated the long-term results of permanent seed implants in men with early stage prostate cancer. Nearly 2,700 men were studied at 11 institutions in the United States over eight years. The radioactive seeds were administered with the aid of ultrasound-guided techniques to precisely position the seeds in the prostate gland. The patients received the seed implants as the only treatment for prostate cancer with no additional chemotherapy or radiation therapy.

"This study is exciting because it shows that brachytherapy alone without additional surgery, radiation, or drugs can be effective at curing early-stage prostate cancer,” said Michael J. Zelefsky, M.D., lead investigator of the study and chief of brachytherapy services at Memorial Sloan-Kettering Cancer Center (New York, NY, USA). "These results also confirm other findings that the quality of the seed implant is a critical ingredient for achieving a better outcome.”



Related Links:
Memorial Sloan-Kettering Cancer Center

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Blood Gas Analyzer
i-Check200
New
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The device combines a minimally invasive, long‑lifetime “read/write” brain‑computer interface (BCI) with assistive devices and AI-driven support (photo courtesy of Epia Neuro)

Implantable Brain-Computer Interface Supports Stroke Recovery and Assistive Function

Stroke leaves many survivors with chronic motor deficits that limit independence, and cognitive decline is a growing concern in aging populations. Stroke is a leading cause of long-term disability in the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.